The effects of in utero HIV and antiretroviral therapy exposure on infant T-cell and monocyte activation, function, and regulation of immune-modulatory pathways
Loading...
Date
Journal Title
Journal ISSN
Volume Title
Publisher
Wiley
Abstract
Human immunodeficiency virus (HIV) infection is characterized by chronic, systemic immune activation. It is unclear how this affects the immune system of infants born to mothers living with HIV (MLWH). The current study assessed whether maternal HIV status and in utero antiretroviral therapy (ART) exposure impact infant T-cell and monocyte activation and regulation, as well as monocyte responsiveness to stimulation at birth and early infancy. T-cell and monocyte activation and expression of immune checkpoint molecules were characterized by means of flow cytometry. Pro- and anti-inflammatory cytokine/chemokine profiles were assessed using a suspension bead array assay. Seventy-one pregnant MLWH and 77 mothers not living with HIV (MNLWH) were recruited at 22 weeks’ gestation, and mother-infant pairs were followed until 6 months postpartum. MLWH had higher percentages of CD4+ and CD8+ T-cells expressing programmed cell death protein-1 (PD-1) and a higher percentage of regulatory T-cells (Tregs). HIV-exposed-but-uninfected (HEU) infants displayed disrupted CD4+ T-cell maturation with an increased number of CD8+ T-cells expressing PD-1 at the time of birth and increased T-cell exhaustion at 10 weeks of age. Higher levels of monocyte activation were observed in MLWH with increased numbers of classical (CL) monocytes expressing CCR2 and CD80. An increased percentage of CL monocytes expressing CCR2 and CD80 was noted in HEU infants at the time of birth, which persisted at 10 weeks of age. Significantly higher levels of C-reactive protein (CRP) and non-significantly higher levels of interleukin (IL)-6 and tumor necrosis factor-alpha were observed in MLWH, indicative of hyperactivated innate inflammation. HEU infants had persistently increased levels of IL-8 and transforming growth factor (TGF)-β1, and lower levels of IL-10, IFN-γ, and CRP. The latter might be secondary to cotrimoxazole use in the HEU infants while the altered cytokine levels might be indicative of altered immune programing. In summary, this cohort study showed that maternal HIV status has a transient effect on basal infant T-cell and monocyte activation, regulation, and monocyte responsiveness, which dissipates at 6 months of age, while altered cytokine levels persisted.
Description
DATA AVAILABILITY STATEMENT : The data that support the findings of this study are available from the corresponding author upon reasonable request.
SUPPORTING INFORMATION : FIGURE S1. Examples of flow cytometry data analysis including A: Basic data clean-up gating strategy; B: UMAP and CITRUS analysis results; C: Infant T-cell t-SNEs depicting Regulatory T-cell clusters expressing CD25, FoxP3 or Helios and D: Examples of t-SNE gating of the monocyte subset. TABLE S1. Infant anthropometric measurements and Z-scores at 10 weeks, 6 months and 12 months of age. TABLE S2. Comparison of CD4+ T-cell maturation stages between mothers living with and without HIV at 28 weeks’ gestation and at the time of birth. TABLE S3. Comparison of CD4+ T-cell maturation stages between HIV-exposed and unexposed infants at birth, ten weeks and at six months age. TABLE S4. Comparison of CD8+ T-cell maturation stages between mothers living with and without HIV at 28 weeks’ gestation and at the time of birth. TABLE S5. Comparison of CD8+ T-cell maturation stages between HIV-exposed and unexposed infants at birth, 10 weeks and 6 months of age. TABLE S6. Percentage of PD-1 expression on CD4+ T-cells between mothers living with and without HIV at 28 weeks’ gestation and the time of birth. TABLE S7. Percentage of PD-1 expression on CD4+ T-cells between HIV-exposed and unexposed infants at birth, 10 weeks and 6 months of age. TABLE S8. Percentage of CD57 expression on CD4+ T-cells between mothers living with and without HIV at 28 weeks’ gestation. TABLE S9. Percentage of CD57 expression on CD4+ T-cells HIV-exposed and unexposed infants at birth, 10 weeks and 6 months of age. TABLE S10. Percentage of PD-1 expression on CD8+ T-cells between mothers living with and without HIV at 28 weeks’ gestation and the time of birth. TABLE S11. Percentage of PD-1 expression on CD8+ T-cells between HIV-exposed and unexposed infants at birth, 10 weeks and 6 months of age. TABLE S12. Percentage of CD57 expression on CD8+ T-cells between mothers living with and without HIV at 28 weeks’ gestation. TABLE S13. Percentage of CD57 expression on CD8+ T-cells between HIV-exposed and unexposed infants at birth, 10 weeks and 6 months of age. TABLE S14. Percentage of regulatory T-cell marker expression on CD4+T-cells between mothers living with and without HIV at the time of birth. TABLE S15. Percentage of regulatory T-cell marker expression on CD4+T-cells between HIV-exposed and unexposed infants from birth to 6 months of age. TABLE S16. Percentage of monocyte marker expression between mothers living with and without HIV at 28 weeks’ gestation and at the time of birth. TABLE S17. Percentage of monocyte marker expression between HIV-exposed and unexposed infants at birth and 10 weeks of age. TABLE S18. Percentage of monocyte marker expression between HIV-exposed and unexposed infants at 6 months of age. TABLE S19. Comparison of the cytokine/chemokine data between the two cohorts of mothers at 28 weeks’ gestation. TABLE S20. Comparison of cytokine/chemokine data between the two cohorts of infants at 10 weeks and 6 months of age. TABLE S21. Comparison of C-reactive protein data between mothers and infants.
Keywords
Human immunodeficiency virus (HIV), Antiretroviral therapy (ART), Mothers living with HIV (MLWH), HIV-exposed-but-uninfected (HEU), Activation, Adaptive, Anti-inflammatory, Exhaustion, Growth, Immunity, Infants, Innate, Pro-inflammatory
Sustainable Development Goals
SDG-03: Good health and well-being
Citation
Prinsloo, A., Steel, H.C., Feucht, U. & Rossouw, T.M. 2026, 'The effects of in utero HIV and antiretroviral therapy exposure on infant T-cell and monocyte activation, function, and regulation of immune-modulatory pathways', Mediators of Inflammation, vol. 2026, art. 2928164, pp. 1-16. https://doi.org/10.1155/mi/2928164.
